Biogen (BIIB) PT Lowered to $340 at Goldman Sachs
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $215.50 -1.62%
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 9 | New: 26
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 9 | New: 26
Join SI Premium – FREE
Goldman Sachs analyst Salveen Richter lowered the price target on Biogen (NASDAQ: BIIB) to $340.00 (from $393.00) while maintaining a Buy rating.
You May Also Be Interested In
- Biogen's Empaveli cuts proteinuria 75% in teens with rare kidney disease
- Manila Electric Co (MER:PM) (MAEOY) PT Lowered to PHP500 at CLSA
- Sumitomo Metal Mining Co Ltd (5713:JP) PT Raised to JPY9,900 at Nomura/Instinet
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
